MK
Michael K. Steinhauser
Chief Executive Officer, Interim Chairman of the Board
Stemedica Cell TechnologiesTherapeutic Areas
Stemedica Cell Technologies Pipeline
| Drug | Indication | Phase |
|---|---|---|
| itMSCs | Chronic Ischemic Stroke | Phase IIb/III |
| itNSCs | Spinal Cord Injury | Development |
| itMSCs + itNSCs | Ischemic Stroke | Research |